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Abstract This work was intended to evaluate the preva-
lence of obstructive small-airway disease in patients with
rheumatoid arthritis (RA) and its association with clinical
characteristics. Pulmonary function testing (PFT) and high-
resolution computed tomography (HRCT) were performed
on 189 consecutive RA patients. Each case was diagnosed
based on abnormal HRCT ﬁndings. We deﬁned obstructive
dysfunction of small airways as a forced expiratory ﬂow
from 25% to 75% of vital capacity (FEF25–75) value[1.96
residual standard deviation (RSD) below predicted values.
We found 19 patients (10.1%) with an interstitial pneu-
monia (IP) pattern and 15 (7.9%) with a bronchiolitis
pattern; the other 155 (82.0%) had no abnormal HRCT
patterns. In patients with neither abnormal pattern, median
values of percentage predicted for carbon monoxide dif-
fusing capacity (DLCO) and ratio of DLCO to alveolar
ventilation (DLco/VA) were within the normal range, but
median FEF25–75, forced expiratory ﬂow at 25% of vital
capacity (V25), and V25/height were \70% of predicted
values. Forty-seven patients (30.3%) in this group had
obstructive small-airway dysfunction. Multivariate logistic
regression analysis indicated that this type of abnormality
is strongly associated with respiratory symptoms [odds
ratio (OR) 5.18; 95% conﬁdence interval (CI) 1.70–15.75;
p = 0.012), smoking history (OR 2.78; 95% CI 1.10–6.99;
p = 0.03), and disease duration[10 years (OR 2.86; 95%
CI 1.27–6.48; p = 0.012). Parenchymal micronodules,
bronchial-wall thickening, and bronchial dilatation on
HRCT scans were also predictive factors for abnormal
FEF25–75, although these morphological changes were too
limited for us to diagnose these patients with the bronchi-
olitis pattern. Obstructive dysfunction of small airways is
apparently common among RA patients, even among those
with neither the IP nor the bronchiolitis pattern on HRCT
scans. Factors signiﬁcantly associated with abnormal
FEF25–75 are respiratory symptoms, smoking history, and
RA duration.
Keywords Disease duration  High-resolution computed
tomography  Pulmonary function test  Rheumatoid
arthritis  Small-airway obstruction
Introduction
Rheumatoid arthritis (RA) is traditionally considered a
chronic disease in which inﬂammatory changes occur
predominantly in the synovial joints, but the systemic
nature of this disease has also been noted in clinical studies
and daily practice. In recent cohort studies, nearly 40% of
patients with RA suffered from some type of extra-articular
manifestations [1–3]. Extra-articular manifestations can be
detected in almost all organ systems as cutaneous, ocular,
hematological, cardiovascular, and pulmonary lesions;
among the most common of these are pulmonary infection
and drug-induced lung disease. Meanwhile, there has been
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associated with RA [4]. Postmortem studies on Japanese
patients with RA have shown that pulmonary involvement
is the second most common cause of death, being directly
responsible for 9.9–17.5% of all mortality [5, 6]. The ﬁg-
ures reported for the prevalence and incidence of pul-
monary involvement in RA vary widely depending on the
criteria used to deﬁne the disease, the sensitivity of the
clinical investigations employed, and the patient popula-
tions examined [7, 8].
The pulmonary manifestations associated with RA have
been evaluated through histopathological, radiological, and
functional approaches. As abnormal radiological patterns
seen on high-resolution computed tomography (HRCT)
scans accurately reﬂect the underlying histological patterns
revealed through lung biopsy [9–11], we recently per-
formed HRCT scans on 126 patients with early or long-
standing RA [12]. By evaluating one or two predominant
abnormalities in each patient’s HRCT ﬁndings and
observing the distribution and extent of all abnormalities in
the lungs, we gave each patient an HRCT-based diagnosis,
such as an interstitial pneumonia (IP) pattern or a bron-
chiolitis pattern. In that study, we noted that a variety of
morphological changes appear on HRCT scans in a con-
siderable proportion of RA patients, though these abnor-
malities were too few for us to categorize such cases as
belonging to the IP or bronchiolitis pattern. It remained
unclear whether such patients may have functional
impairment of the lung and whether such abnormalities are
related to RA.
In this study, we performed pulmonary function testing
(PFT) and HRCT scanning on 189 consecutive RA
patients. These were categorized according to their HRCT
ﬁndings into the following three groups: patients with the
IP pattern, patients with the bronchiolitis pattern, and
patients who were not diagnosed with any abnormal HRCT
pattern. The functional abnormalities and clinical charac-
teristics of these groups were compared. In addition, the
prevalence of obstructive dysfunction in small airways
among RA patients without the IP or bronchiolitis pattern
on HRCT scans was determined. Finally, predictive factors
for the presence of such functional abnormalities were
identiﬁed through multivariate logistic regression analysis.
Patients and methods
Patients
Study participants were 189 Japanese patients with RA
who had visited our outpatient clinic between January and
May 2009. Patients were excluded from this study if they
had any of the following histories: (1) pulmonary diseases
precluding an accurate pulmonary evaluation; (2) other
collagen–vascular/autoimmune diseases; (3) exposure to
dust such as asbestos or silica; or (4) thoracic radiation for
cancer therapy. Of the initial population (n = 231), 42
patients were excluded for meeting one of the above-
mentioned criteria; speciﬁc reasons for exclusion were as
follows: atypical mycobacterial disease (n = 1), chronic
bronchitis (n = 2), emphysema (n = 19), Sjo ¨gren’s syn-
drome (n = 7), pleural involvement (n = 1), asbestosis
(n = 1), clinically evident bronchiectasis (n = 2), bron-
chial asthma (n = 3), and middle lobe syndrome (n = 6).
All participants fulﬁlled the 1987 American College of
Rheumatology (ACR) criteria for diagnosis of RA. The
ethics committee of our hospital approved the study pro-
tocol, and informed consent was obtained from all patients.
HRCT scanning and evaluation
A Somatom Sensation 4D CT scanner (Siemens, Erlangen,
Germany) was used in this study. Thin-section scans were
obtained with 2-mm collimation at 10-mm intervals,
extending from the lung apices to the diaphragm. Technical
factors were 120 kV and 130 mA. Images were recon-
structed with a high-spatial-frequency algorithm. HRCT
examinations were performed with patients in the supine
position, at the suspended end-inspiratory volume, with
imaging times of 1 s. All images were obtained at window
levels appropriate for the lung parenchyma settings
(window width 1,300–1,500 HU; window level -750 to
-650 HU), and mediastinum (window width 400 HU;
window level 30–50 HU). Images were reviewed in ran-
dom order and independently by two observers (YK and
SM) who were blinded to the patients’ clinical status and
PFT results. In the event of a disagreement, the ﬁnal
decision was made by consensus. Abnormal HRCT ﬁnd-
ings were deﬁned according to the criteria described in our
previous report [12]. For each case, we examined one or
two predominant HRCT ﬁndings as well as the distribution
and extent of abnormal ﬁndings and determined the prob-
able diagnosis related to these pulmonary abnormalities
according to the criteria on HRCT patterns deﬁned by
Tanaka et al. [9].
Pulmonary function tests
PFTs were performed on RA patients with or without
abnormal HRCT patterns using a standard protocol. Vital
capacity (VC), forced vital capacity (FVC), residual volume
(RV)/totallungcapacity(TLC),forcedexpiratoryvolumein
theﬁrstsecond(FEV1),FEV1/FVCratio(asensitiveindexof
overall airwayobstruction),and forcedexpiratory ﬂowfrom
25% to 75% of VC (FEF25–75, a speciﬁc index of small air-
way function) were measured using a rolling-seal type of
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123spirometer (Chestac 8800; Chest Inc., Tokyo, Japan), with
participants in a seated position. Peak expiratory ﬂow (PEF)
and forced expiratory ﬂow at 25%, 50%, and 75% of VC
(V25,V 50, and V75) were also recorded. Diffusing capacity
for carbon monoxide (DLCO) and DLCO/alveolar volume
(VA), indices of restrictive interstitial disease, were evalu-
ated by a single-breath method using the same equipment.
All PFTs were administered by two technicians who have a
great deal of experience in performing high-quality PFTs.
Measured values were compared with normal predicted
values based on age, gender, and height of the individual,
using regression equations installed in the spirometer; the
equation for RV/TLC was formulated by Grimby and
Soderholm [13], that for FEF25–75 by Schmidt et al. [14],
those for PEF and V75 by Cherniack and Raber [15], that for
V25/height (Ht) by Yamamoto and Mitsufuji [16], and those
for DLCO and DLCO/VA by Burrows et al. [17]. These
regression equations are widely used in Japan to calculate
normal predicted values. Measured values for VC, FVC,
FEV1/FVC,V50,andV25werecomparedwithnormalvalues
determined by regression equations based on data from a
sample of the general Japanese population and ofﬁcially
approved by the Japanese Respiratory Society (JRS state-
ment 2001, http://www.jrs.or.jp/quicklink/glsm/index.html).
Results are expressed as a ratio of measured to predicted
values (%predicted) unlessotherwise indicated. Wedeﬁned
a patient as having small-airway obstruction if that patient’s
measured FEF25–75 value was [1.96 residual standard
deviation (RSD) below the predicted value. This threshold
marks the lower 95% conﬁdence limit in a normal distribu-
tion; thus, 2.5% of the population will lie outside the normal
range at the lower end [18, 19].
Statistical analysis
In univariate analyses of categorical variables, levels of
signiﬁcance were determined by means of the chi-square
test using 2 9 2 contingency tables. If cell values were\5,
Fisher’s exact probability test was used. Continuous vari-
ables were assessed using the Mann–Whitney U test.
Multivariate logistic regression analysis was used to eval-
uate correlations between PFT abnormalities (as response
variables) and a set of predictor variables, including age,
disease duration ([10 years), respiratory symptoms,
smoking history, and presence of anticyclic citrullinated
peptide antibodies (anti-CCP Abs). A backward stepwise
selection procedure was used to select signiﬁcant predictor
variables. The strength of association between functional
abnormalities and these predictors was estimated using
odds ratios (OR) and 95% conﬁdence intervals (CI). In
addition, the receiver operating characteristic (ROC)
curves and the corresponding area under the curve (AUC)
were calculated to provide an index of validity of
multivariate logistic regression models. For the construc-
tion of ROC curves, the true positive (sensitivity) and
false positive (1-speciﬁcity) rates were plotted as the
y and x axes, respectively. For all tests, probability values
(p values) \0.05 were considered to indicate statistical
signiﬁcance. All calculations were performed using either
Excel Statistical Analysis 2008 (SSRI Co., Ltd., Tokyo,
Japan) or PASW Statistics version 17 (SPSS Japan Inc.,
Tokyo, Japan).
Results
Baseline characteristics of RA patients
with or without abnormal HRCT patterns
Of the 189 patients examined, 34 (18.0%) were diagnosed
with the IP pattern (n = 19) or the bronchiolitis pattern
(n = 15) of HRCT abnormalities. In the other 155 patients
(82.0%), the distribution and extent of abnormal HRCT
ﬁndings were insufﬁcient to warrant a diagnosis of abnor-
mal HRCT patterns. As shown in Table 1,the patients in the
IP group and those in the bronchiolitis group were more
likely to complain of respiratory symptoms at the time of
enrollment than were those without abnormal HRCT pat-
terns (p = 0.002 and 0.000, respectively). C-reactive pro-
tein (CRP) levels and erythrocyte sedimentation rates
(ESR) were signiﬁcantly higher in these two patient groups
(CRP, p = 0.042 and 0.004, respectively; ESR, p = 0.002
and 0.005, respectively). The median age of both groups
was signiﬁcantly older than that of patients without abnor-
mal HRCT patterns (p = 0.0002 and 0.031, respectively).
In addition, disease duration of patients with the bronchi-
olitis pattern was signiﬁcantly longer than that of patients
without abnormal HRCT patterns (p = 0.037); in none of
the bronchiolitis-pattern patients was it \2 years. The
patients in this group were more likely to suffer from severe
joint damage, though this tendency did not reach statistical
signiﬁcance (p = 0.055). Parenchymal micronodules and
bronchial-wall thickening, both of which are indicative of
small-airway diseases, were more prominent in the bron-
chiolitis group (p = 0.000). Likewise, the frequency of
bronchial dilatation was signiﬁcantly higher in this patient
population (p = 0.004).
PFTs of RA patients with or without abnormal HRCT
patterns
The characteristic defects seen in PFTs of patients with the
bronchiolitis pattern are those considered to indicate air-
way obstruction; obstructive defects in small airways were
particularly prominent, as shown by decreases in FEF25–75,
V50-Jpn, V25-Jpn, and V25/Ht to less than 50% of their
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123predicted values (Table 2). In patients diagnosed with the
IP pattern, the median % predicted values for DLCO and
DLCO/VA, indices of restrictive changes, were signiﬁcantly
decreased. In the patient group with no abnormal pattern,
median values of FEV1/FVC and % predicted for DLCO
and DLCO/VA were within the normal range. It is worth
noting that the median % predicted values for FEF25–75,
V25-Jpn, and V25/Ht were markedly reduced (less than 70%
of predicted values) in this patient group. These data show
that obstructive changes in small, distal airways are present
even in RA patients who have not been diagnosed with the
bronchiolitis pattern seen on HRCT scans.
Correlation between clinical characteristics and PFT
ﬁndings in RA patients without abnormal HRCT
patterns
When we deﬁned abnormal FEF25–75 as an FEF25–75 value
[1.64 RSD below the predicted values, 13 patients
(86.7%) in the bronchiolitis group (n = 15) and four
(21.1%) in the IP group (n = 19) were diagnosed with
obstructive dysfunction in small airways. When we deﬁned
abnormal FEF25–75 as an FEF25–75 value[1.96 RSD below
the predicted values, 11 patients (73.3%) in the former
group and three (15.8%) in the latter were diagnosed with
obstructive dysfunction in small airways. Among the 155
patients with neither abnormal HRCT pattern, 64 (41.3%)
and 47 (30.3%) patients had FEF25–75 values [1.64 RSD
and [1.96 RSD below predicted values, respectively
(Table 3). Thus, obstructive dysfunction of small airways
appears to be common in RA patients, including those
without the IP or bronchiolitis HRCT pattern. In a com-
parison of patients in this group with measured FEF25–75
values [1.96 RSD below predicted values and the
remainder of this patient group, low FEF25–75 values are
more often seen in patients complaining of respiratory
symptoms (OR 5.19; p = 0.001), those with smoking his-
tory (OR 2.57; p = 0.027), and those with disease duration
[10 years (OR 2.35; p = 0.026). Bronchial/bronchiolar
HRCT abnormalities such as parenchymal micronodules
(OR 30.80; p = 0.000) and bronchial-wall thickening (OR
32.69; p = 0.000) were more frequently seen in patients
with abnormal FEF25–75 (Table 3). The frequency of
bronchial dilatation was also signiﬁcantly higher in this
group (OR 5.13; p = 0.0000), although these patients had
not experienced clinically evident bronchiectasis. There
was no signiﬁcant difference in proportions of current
steroid users between patients with abnormal FEF25–75
Table 1 Clinical characteristics of rheumatoid arthritis (RA) patients with or without abnormal high-resolution computed tomography (HRCT)
patterns
No abnormal
pattern (n = 155)
IP pattern
(n = 19
a)
P value* Bronchiolitis
pattern (n = 15)
P value*
Male/female 25/130 6/13 0.097 0/15 0.13
Age, years, median (25th, 75th percentiles) 60.0 (52.0, 70.0) 72.0 (68.0, 76.0) 0.0002 63.0 (59.0, 75.0) 0.031
Disease duration, years, median (25th, 75th percentiles) 4.0 (2.0, 9.0) 7.0 (3.0, 14.0) 0.45 7.0 (4.0, 13.0) 0.037
\2 years, numbers of patients (%) 42 (27.1) 3 (15.8) 0.41 0 0.024
[10 years, numbers of patients (%) 38 (24.5) 6 (31.6) 0.50 5 (33.3) 0.45
Steinbroker stage (III and IV), numbers of patients (%) 69 (44.6) 10 (52.6) 0.50 11 (73.4) 0.055
Respiratory symptoms, number of patients (%) 17 (11.0) 7 (36.8) 0.002 12 (80) 0.000
Current or former smokers
b, numbers of patients (%) 27 (17.4) 5 (26.3) 0.34 2 (13.3) 1.00
Positive anti-CCP Abs 139 (89.7) 18 (94.7) 0.70 11 (73.3) 0.081
Positive RF 136 (87.7) 19 (100) 0.23 12 (80) 0.42
CRP, mg/dl, median (25th, 75th percentiles) 0.2 (0.06, 0.7) 0.3 (0.2, 1.1) 0.042 0.8 (0.3, 2.1) 0.004
ESR, mm/h, median (25th, 75th percentiles) 23.0 (14.0, 40.0) 39.0 (27.0, 59.0) 0.002 38.0 (32.0, 55.0) 0.005
Abnormal HRCT ﬁndings, numbers of patients (%)
Parenchymal micronodules 25 (16.1) 1 (5.3) 0.31 14 (93.3) 0.000
Bronchial wall thickening 12 (7.7) 0 0.37 11 (73.3) 0.000
Bronchial dilatation 47 (30.3) 4 (21.1) 0.40 10 (66.7) 0.004
IP interstitial pneumonia, anti-CCP Abs anticyclic citrullinated peptide antibodies, RF rheumatoid factor, CRP C-reactive protein, ESR eryth-
rocyte sedimentation rate
* p values are based on comparison with patients without any abnormal HRCT patterns
a One case may be considered to exhibit a mixed HRCT pattern, because the patient’s HRCT revealed ground-glass attenuation, reticulation, and
parenchymal micronodules as the predominant abnormalities. Nevertheless, we ﬁnally reached a consensus that the most predominant HRCT
ﬁnding was ground-glass attenuation
b C10 pack-years; one pack-year is deﬁned as 20 manufactured cigarettes (1 pack) smoked per day for 1 year
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123(nine out of 47, 19.1%) and those without this abnormality
(13 out of 108, 12.0%).
Multivariate logistic regression analysis with a back-
ward stepwise selection procedure conﬁrmed that the
presence of respiratory symptoms (OR 5.18, p = 0.012),
smoking history (OR 2.78; p = 0.03), and disease duration
[10 years (OR 2.86; p = 0.012) are signiﬁcant factors
independently associated with obstructive changes in small
airways of RA patients who have neither IP nor bronchi-
olitis HRCT pattern (Table 4). The ROC curve showed that
the ﬁnal prediction model was moderately accurate (AUC,
0.71; 95% CI, 0.62–0.80; p = 0.000).
Discussion
Rheumatoid arthritis is known to cause upper- and lower-
airway disease. The presence of functional and/or mor-
phological abnormalities in small airways has recently
been noted in RA patients, but the prevalence and clinical
signiﬁcance of bronchiolar disease is still a subject of
debate [20]. The reported prevalence of obstructive dys-
function in small airways in RA patients, estimated on the
basis of decreases in FEF25-75 values, varies among studies,
ranging from 8% to 65% (Table 5). This variation may be
explained by the different criteria used in different studies
to assess small-airway disease as well as by variation in the
patient populations examined. Some studies performed
PFTs only on RA patients without pulmonary symptoms or
with normal chest radiographs [21–23]; others included
unselected RA patients [24–31]. Percentages of patients
with cigarette exposure also vary among studies, ranging
from 14.6% to 76.7%. To deﬁne FEF25–75 abnormality,
some investigators used the lower 90% or 95% conﬁdence
limit (i.e., 1.64 RSD or 1.96 RSD below the predicted
values) [22, 26–28, 31], whereas others used ﬁxed per-
centages of predicted values [21, 24, 25, 29, 30]. The
participants in this study had no abnormal HRCT patterns,
and 17.4% were former or current smokers. Seventeen
(11.0%) complained of respiratory symptoms. We deﬁned
small airway dysfunction using the lower 95% conﬁdence
limit for FEF25–75 (\-1.96 RSD), which was determined
by the regression equation of Schmidt et al. [14]. We
concluded that under these conditions, the prevalence of
obstructive small-airway disease in RA patients without the
IP or bronchiolitis HRCT pattern is 30.3%. Application of
the regression equation derived from the data of Quanjer
et al. [18] decreased the prevalence of small-airway
obstruction in this patient group somewhat, but the prev-
alence was still relatively high (Table 5). Normal values
predicted for particular ages, genders, and heights may
vary among different ethnic groups; unfortunately, no
regression equation for FEF25–75 based on a Japanese ref-
erence population is available.
Table 2 Pulmonary function tests of rheumatoid arthritis (RA) patients with or without abnormal high-resolution computed tomography
(HRCT) patterns
No abnormal patterns
% predicted (n = 155)
IP pattern
% predicted (n = 19)
Bronchiolitis pattern
% predicted (n = 19)
VC-Jpn 101.8 (90.3, 112.0) 98.0 (86.2, 108.2) 85.4 (77.5, 107.6)*
FVC-Jpn 107.6 (94.8, 117.6) 100.5 (86.9, 115.0) 87.7 (82.6, 113.8)*
RV/TLC 109.6 (99.1, 122) 107.1 (96.5, 125.6) 122.0 (115.4, 129.7)**
FEV1/FVC
a 79.0 (74.3, 83.3) 82.3 (76.4, 87.3)* 72.0 (63.5, 77.4)***
FEV1-Jpn 101.2 (90.5, 115.1) 102.3 (90.9, 118.2) 83.0 (69.2, 101.1)***
FEF25–75 65.7 (49.0, 86.9) 82.6 (57.9, 110.9)* 38.1 (22.5, 56.1)***
PEF 72.4 (63, 81.4) 71.6 (61.5, 83.1) 53.4 (49.3, 67.8)***
V75 90.2 (76.6, 100.4) 89.5 (71.0, 97.4) 58.9 (41.2, 73.7)***
V50-Jpn 78.8 (59.1, 104.2) 92.7 (67.0, 140.3)* 47.2 (30.8, 51.7)***
V25-Jpn 52.8 (37.8, 71.8) 69.2 (39.8, 125.3)* 29.2 (25.3, 48.2)***
V25/Ht 36.5 (27.6, 55) 47.9 (32.2, 72.8) 19.6 (12.5, 27.7)***
DLCO 103 (91.5, 116.5) 82.3 (72.6, 97.0)*** 96.3 (72.3, 113.7)
DLCO/VA 82.3 (72.6, 93.7) 71.8 (57.4, 80.6)** 76.7 (71.6, 87.3)
Data are expressed as median (25th, 75th percentiles)
IP interstitial pneumonia, Jpn the Japanese reference population, VC vital capacity, FVC forced vital capacity, RV residual volume, TLC total
lung capacity, FEV1 forced expiratory volume in one second, FEF25–75 forced expiratory ﬂow from 25 to 75% of VC, PEF peak expiratory ﬂow,
V25, V50, and V75 forced expiratory ﬂow at 25, 50, and 75% of VC, Ht height, DLCO diffusing capacity for carbon monoxide, VA alveolar volume
* p\0.05, **p\0.01, and ***p\0.001 compared with patients without the abnormal HRCT patterns
a Data are actual values, not % predicted
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RA remains to be elucidated. In a 10-year follow-up study,
Fuld et al. [32] showed that PFT abnormality is a common
ﬁnding in nonsmoking, asymptomatic patients with RA and
that its incidence does not increase over time. These data
may suggestthat obstructive changesin the small airwayare
simplybenignﬁndings,thoughFEF25–75datawereavailable
for only a small subset of their patients. In contrast, Avnon
et al. [23] showed that 13.2% of RA patients participating in
a 5-year follow-up study recently developed small-airway
defect, deﬁned as reduced FEF25–75. Vergnenegre et al.
reported a signiﬁcant correlation between abnormal
FEF25–75 and duration of articular disease in nonsmokers
with RA [28]. Similarly, through both univariate and
Table 3 Association of small-airway dysfunction with clinical and radiological characteristics in rheumatoid arthritis (RA) patients without
abnormal high-resolution computed tomography (HRCT) patterns
FEF25–75 P FEF25–75 P
\-1.64 RSD
(n = 64)
C-1.64 RSD
(n = 91)
\-1.96 RSD
(n = 47)
C-1.96 RSD
(n = 108)
Female 53 (82.8) 77 (84.6) 0.76 38 (80.9) 92 (85.2) 0.50
Age, years, median (25th, 75th percentiles) 61.5 (54.0, 67.8) 59 (52.0, 70.0) 0.58 62.0 (56.0, 69.0) 59.0 (52.0, 70.0) 0.39
Disease duration, years, median (25th, 75th
percentiles)
4.0 (2.0, 10.8) 4.0 (3.0, 8.0) 0.41 5.0 (2.0, 11.0) 4.0 (3.0, 8.0) 0.37
\2 years, numbers of patients (%) 18 (28.1) 24 (26.4) 0.81 14 (29.8) 28 (25.9) 0.62
[10 years, numbers of patients (%) 20 (31.3) 18 (19.8) 0.10 17 (36.2) 21 (19.4) 0.026
a
Steinbroker stage (III and IV), numbers of patients (%) 29 (45.3) 40 (44.0) 0.87 22 (46.8) 47 (43.5) 0.70
Respiratory symptoms, numbers of patients (%) 13 (20.3) 4 (4.4) 0.003 11 (23.4) 6 (5.6) 0.001
b
Current or former smokers
g, numbers of patients (%) 15 (23.4) 12 (13.2) 0.098 13 (27.7) 14 (13.0) 0.027
c
Positive anti-CCP Abs, numbers of patients (%) 55 (85.9) 84 (92.3) 0.20 40 (85.1) 99 (91.7) 0.22
Positive RF, numbers of patients (%) 55 (85.9) 81 (89.0) 0.57 41 (87.2) 95 (88.0) 0.90
CRP, mg/dl, median (25th, 75th percentiles) 0.3 (0.1, 0.8) 0.2 (0.05, 0.7) 0.14 0.3 (0.1, 0.8) 0.2 (0.05, 0.7) 0.11
ESR, mm/h, median (25th, 75th percentiles) 28.0 (16.0, 44.0) 21.0 (14.0, 38.0) 0.06 26.0 (14.0, 40.0) 21.5 (14.3, 39.5) 0.48
Abnormal HRCT ﬁndings, numbers of patients (%)
Parenchymal micronodules 22 (34.4) 3 (3.3) 0.0000 22 (46.8) 3 (2.8) 0.000
d
Bronchial wall thickening 11 (17.2) 1 (1.1) 0.0003 11 (23.4) 1 (0.9) 0.000
e
Bronchial dilatation 29 (45.3) 18 (19.8) 0.0007 26 (55.3) 21 (19.4) 0.000
f
FEF25–75 forced expiratory ﬂow from 25% to 75% of vital capacity, RSD residual standard deviation, anti-CCP Abs anticyclic citrullinated
peptide antibodies, RF rheumatoid factor, CRP C-reactive protein, ESR erythrocyte sedimentation rate
Odds ratios (95% conﬁdence intervals) were 2.35 (1.10–5.03)
a, 5.19 (1.79–15.07)
b, 2.57 (1.10–6.01)
c, 30.80 (8.54–111.08)
d, 32.69
(4.08–262.14)
e, and 5.13 (2.43–10.82)
f, respectively
g C10 pack-years; one pack-year is deﬁned as 20 manufactured cigarettes (1 pack) smoked per day for 1 year
Table 4 Predictive factors for functional impairment in small airways of rheumatoid arthritis (RA) patients without abnormal high-resolution
computed tomography (HRCT) patterns
Univariate analysis Multivariate analysis
OR (95% CI) P value OR (95% CI) P value
FEF25–75\-1.96 RSD
Respiratory symptoms 5.19 (1.79–15.07) 0.001 5.18 (1.70–15.75) 0.012
Smoking history ([10 pack-years) 2.57 (1.10–6.01) 0.027 2.78 (1.10–6.99) 0.030
Disease duration[10 years 2.35 (1.10–5.03) 0.026 2.86 (1.27–6.48) 0.012
In the multivariate logistic regression analysis, low FEF25–75 (\-1.96 RSD) was used as the dependent variable. Age, disease duration
([10 years), respiratory symptoms, smoking history, and presence of anticyclic citrullinated peptide antibodies were entered as the predictor
variables (independent variables). In the ﬁnal step, a signiﬁcant inﬂuence of respiratory symptoms, disease duration ([10 years), and smoking
history was detected, yielding an area under the receiver operating characteristic curve of 0.71
OR odds ratio, 95% CI 95% conﬁdence interval, RSD residual standard deviation, FEF25–75 forced expiratory ﬂow from 25% to 75% of vital
capacity
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123multivariate analyses, we found that longer disease duration
([10 years) is a strong predictor for the presence of small-
airway dysfunctiondeﬁned as abnormal FEF25–75 (Table 4).
These ﬁndings may suggest that small-airway disease has a
long-term clinical signiﬁcance as a manifestation of RA. In
its early stages, obstructive changes in small airways are
subtle, which makes it difﬁcult to deﬁnitively diagnose the
bronchiolitis pattern in HRCT images. Among these cases,
some subset may subsequently develop clinically evident
andHRCT-conﬁrmedbronchiolitisduringthecourseofRA.
Indeed, we previously reported that bronchiolar abnormali-
ties on HRCT scans are associated with RA duration [12].
Long-term follow-up studies are required to determine
whetherobstructivedysfunction insmallairwaysisabenign
ﬁnding or a predictive factor for future development of
bronchiolitis. In this study, we showed that the presence of
respiratorysymptomsisstronglyassociatedwithobstructive
abnormalities of small airways (Table 4). Thus, PFTs are
encouraged for RA patients who have respiratory symptoms
and disease durations[10 years, even if the distribution and
extent of the HRCT abnormalities in their lungs are not yet
sufﬁcient to warrant a diagnosis of bronchiolitis.
The contribution of RA to small-airway disease is
obscured by the inﬂuence of other risk factors, such as
cigarette smoking. We have shown that in patients with
neither IP nor bronchiolitis HRCT pattern, the frequency of
obstructive changes in small airways was likely to depend,
at least in part, on tobacco exposure (Table 4). As Table 5
shows, several studies have found signiﬁcant differences in
the rates of small-airway disease between cigarette smokers
with RA and nonsmokers with RA [24–26]. Small-airway
obstruction may be secondary to cigarette smoking rather
than to RA per se. Nevertheless, the frequency of small-
airway dysfunction is still high in nonsmokers with RA [21,
28]. Its incidence has ranged from 13.2% to 36% in studies
on patients with relatively lower rates (14.6–25.6%) of
smoking history [23, 27, 29, 31]. Based on open lung
biopsies, Hakala et al. [33] have suggested that smoking
Table 5 Prevalence of small-airway dysfunction among rheumatoid arthritis (RA) patients on basis of reduced forced expiratory ﬂow from 25%
to 75% of vital capacity (FEF25–75)
No. of
patients
Patient
population
No. of current or
former smokers (%)
Deﬁnition of
abnormal FEF25–75
No. of patients having
small-airway disease (%)
Collins et al. [24] 43 Unselected 33 (76.7) \80% of predicted 28 (65.1)
(92.9% had smoking history)
Geddes et al. [21] 100 Normal chest X-rays 53 (53) \40% of predicted 38 (38)
[14 (29.8) in nonsmokers]
Mountz et al. [25] 26 Unselected 14 (53.8) \65% of predicted 12 (46.2)
[9 (64.3) in smokers]
Banks et al. [26] 270 Unselected NA \-2 RSD 31 (11.5)
(87.1% had smoking history)
Cortet et al. [27] 68 Unselected 16 (23.5) \-1.64 RSD (\the lower 90%
conﬁdence limit)
9 (13.2)
Vergnenegre et al. [28] 100 Unselected 19 (19) \-1.64 RSD 18 (18)
[14 (17.3) in nonsmokers]
Perez et al. [22] 50 Normal chest X-rays 11 (22) \-1.64 RSD and/or phase III
slope
a [2S D
4 (8)
Zrour et al. [29] 75 Unselected 11 (14.6) \80% of predicted 27 (36)
Chung et al. [30] 39 Unselected NA \40% of predicted 16 (41.0)
Kanat et al. [31] 54 Unselected 12 (22.2) \the lower 95% conﬁdence limit
(\-1.96 RSD)
8 (14.8)
Avnon et al. [23] 82 No symptom or
evidence of
respiratory disease
21 (25.6) Reduced FEF25–75 12 (14.6)
This study 155 No HRCT-based
diagnosis of
lung disease
27 (17.4) \-1.64 RSD (Schmidt)
\-1.96 RSD (Schmidt)
\-1.64 RSD (Quanjer)
\-1.96 RSD (Quanjer)
64 (41.3)
47 (30.3)
38 (24.5)
22 (14.2)
FEF25–75 forced expiratory ﬂow from 25% to 75% of vital capacity, NA not available, RSD residual standard deviation, HRCT high-resolution
computed tomography
a The slope of phase III was determined by single-breath nitrogen washout test
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123alone cannot explain the development of bronchiolar
lesions in patients with connective tissue diseases such as
RA. These ﬁndings appear to be explained by an additive
effect of RA and cigarette smoking on small-airway func-
tion; smoking exposure may potentiate and exacerbate
RA-associated development of small-airway disease.
Several studies have suggested that the reduction in
FEF25–75 seen in RA patients may reﬂect restrictive changes
due to RA-associated interstitial lung disease [24, 26].
Interstitial ﬁbrosis of the peribronchiolar areas may cause
obstruction instead of restriction. Begin et al. [34] reported
on six nonsmokers with RA and airway limitations; open
lung biopsies of these cases showed inﬂammatory reaction
and ﬁbrotic proliferation in the peribronchiolar tissues,
leading to complete obliteration of many bronchioles.
Elsewhere, a high prevalence (8%) of small airway
involvement was seen in RA patients without radiographic
evidence of interstitial lung disease [22]. In our study, like-
wise, no restrictive ventilator disturbance on PFT was evi-
dent in the patient group without the IP or bronchiolitis
pattern (Table 2). Sjo ¨gren’s syndrome, which is often
associated with RA, has been noted to cause peribronchiolar
lymphocytic inﬂammation, subclinically leading to
obstructive small-airway abnormalities [34–36]. Whether
the complication of Sjo ¨gren’s syndrome is a major contrib-
utor to the development of small-airway disease in RA
patients remains to be elucidated. Perez et al. [22] showed
that the presence of secondary Sjo ¨gren’s syndrome is not
related to abnormalPFT ﬁndings. Patientswho had ahistory
ofSjo ¨gren’ssyndromewereexcludedfromourstudy,andno
participants revealed any clinical evidence of developing
secondary Sjo ¨gren’s syndrome during the subsequent fol-
low-up period.
Anti-RA drugs such as penicillamine and gold have
been associated with obliterative bronchiolitis [7, 37, 38].
None of the patients in our study had been treated with
penicillamine or gold, however. Among our patients
without an IP or bronchiolitis HRCT pattern, 143 (92.3%)
had received methotrexate (MTX) at low dosages
(6–10 mg/week); therefore, we cannot exclude the possi-
bility that MTX use may inﬂuence small-airway function
during the disease course, although there is no evidence to
suggest that MTX use at low doses is associated with small
airway function in RA patients, and most studies have
found only minor subclinical alterations in pulmonary
function in RA patients who have been treated with MTX
at low doses [7, 39]. In our studies, we have found no
signiﬁcant differences in the duration or cumulative dosage
of MTX therapy between patients with small-airway
obstruction and those without (data not shown).
The reason for the high incidence of small-airway
obstruction in RA patients remains unclear. One of the most
attractive explanations is that the obstructive changes are
due to frequent and recurrent infections in the small air-
ways. Colonization of the small airways by pathogenic
microorganisms has been reported in patients with clini-
cally stable bronchiectasis [40, 41], and a number of HRCT
studies have shown that bronchiectasis is common among
RA patients [22, 42–45]. We have also reported that bron-
chial dilatation is the most frequent HRCT ﬁnding both in
patients with early RA and in those with longstanding RA
[12]. Furthermore, in the study reported here, the preva-
lence of bronchial dilatation on HRCT scans was signiﬁ-
cantly higher in patients with abnormal FEF25–75 values
(Table 3). Cortet et al. [27] also reported that bronchiectasis
is more frequently seen in RA patients with low FEF25–75
values. Taken together, the evidence indicates that RA
patients may have an increased susceptibility to airway
infections or a reduced ability to eradicate these infections.
Chronic colonization, secondary persistent inﬂammation,
and progressive lung injury may contribute to the frequent
development of airway obstruction during the disease
course. In addition to bronchiectasis, there are several RA-
related factors that are likely to increase the incidence of
repeated bronchiolar infections. For example, orally
administered steroids predispose RA patients to lower
respiratory tract infection [46, 47]. In our study, however,
the rates of orally administered steroid therapy were similar
between patients with small-airway obstruction and those
without. As an alternative explanation, several studies have
proposed that bronchi/bronchioles are one of the main tar-
gets of autoimmunity in RA patients. Bronchiolar inﬂam-
mation may secondarily induce mucosal edema, which
eventually leads to development of small-airway obstruc-
tion [48]. Such pulmonary lesions may create a favorable
environment for persistent infections. It is uncertain whe-
ther microbial colonization may precede bronchiolar
obstructive changes or not. Regardless of which came ﬁrst,
a vicious spiral of infections and obstructive changes in the
small airways can develop in the lungs of RA patients.
We found that among patients without abnormal HRCT
patterns, there is no signiﬁcant association between the
presence of small-airway obstruction and the levels of
CRP and ESR at the time of enrollment (Table 3). Perez
et al. [22] also reported no correlation between RA-related
parameters and small-airway dysfunction, deﬁned as
abnormal FEF25–75. However, we cannot entirely rule out
the possibility of a relationship between RA activity and
small-airway disease, because disease activity varies over
time. Time-integrated values of disease activity markers
more accurately reﬂect the cumulative effects of disease
activity during the course of RA; therefore, serial mea-
surements of disease activity, starting in the early stages of
RA, are required to address this question. The relationship
between joint damage and small-airway obstruction is an
important issue. As Table 3 shows, there were no signiﬁcant
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123difference between patients with abnormal FEF25–75 and
those without in the rate of classiﬁcation into Steinbroker
stage III or IV. However, more sensitive assessment of joint
damage may be required for a comparison among patients
in the group without abnormal HRCT patterns.
In conclusion, we obtained evidence suggesting that
obstructive dysfunction of small airways is common among
RA patients, even among those without a diagnosis of IP or
bronchiolitis pattern of HRCT abnormalities. The presence
of respiratory symptoms, positive smoking history, and
disease duration[10 years were predictive factors for the
presence of abnormal FEF25–75. This type of functional
abnormality was more often seen in patients with bron-
chial/bronchiolar abnormalities on HRCT scans, although
the distribution and extent of these patients’ HRCT
abnormalities were too limited to warrant a diagnosis of the
bronchiolitis pattern. Restrictive disturbance was not evi-
dent in this patient group. The precise characterization of
obstructive changes in small airways that is enabled by
both PFT and HRCT appears to be helpful in evaluating
not only their long-term signiﬁcance as pulmonary com-
plications of RA but also their implication in RA
pathogenesis.
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